Business
Positive data of Pollinex Quattro Grass vaccine
Positive data of Pollinex Quattro Grass vaccine.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 4286S Allergy Therapeutics PLC 25 June 2018 \n\n \n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Group\")\n \nAllergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy\n \n25 June 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the publication of positive data in the journal Immunotherapy, demonstrating long-lasting efficacy of Pollinex Quattro Grass in patients with grass pollen allergy. Zielen et al., Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy. doi; 10.2217/imt-2018-0004 (ePub ahead of print).\n \nThe observational study, led by Professor Stefan Zielen of the Goethe University, Germany, focused on the long-term efficacy of Pollinex Quattro Grass. Each of the clinical symptoms (runny nose, sneezing and conjunctivitis) were statistically significantly reduced in treated patients compared with controls without allergen-specific immunotherapy. The study concluded that patients treated with Pollinex Quattro Grass vaccine exhibited significant and long-lasting symptom improvements 3-6 years after cessation of treatment.\n \nProfessor Stefan Zielen, author of the paper commented; \"We are delighted with the publication of our observational study that demonstrates the long-term effects of Pollinex Quattro Grass immunotherapy. Our paper highlights the benefits that this allergen-specific immunotherapy can offer allergy sufferers, in terms of patient convenience, as well as the potential for positive and long-lasting effects.\"\n \nManuel Llobet, CEO at Allergy Therapeutics, said: \"This paper validates earlier studies indicating Pollinex Quattro is disease modifying for the many patients affected by grass allergy. Together with the recently announced positive data from our Phase Grass G205 clinical study, we believe that we have a robust data set for our suite of novel allergy product candidates. We look forward to commencing further studies with the goal of developing a strong allergy portfolio to patients globally, including in the significant US market.\"\n \nThe data presented supports earlier...